Majem, Margarita

AbstractTo describe the clinical outcomes and risk factors for 90‐day mortality in patients with solid tumours (ST) and coronavirus disease 2019 (COVID‐19) during the first outbreak in Catalonia. This is a multicentre retrospective study including adults with ST and COVID‐19 confirmed by real time reverse transcription polymerase chain reaction between 13 March and 30 April 2020. Clinical and survival data were collected. Follow‐up ended on 30 July 2020. Multivariate and survival analysis were performed. A hundred and fifteen patients were included. In all, 42.6% had advanced disease and were receiving anticancer treatment; 7% were admitted to the ICU and 22.6% died during hospitalisation. Thirty‐day mortality was 27.8%, which increased to 33.9% at 90 days. Ninety‐day mortality was associated with current smoker status (hazard ratio [HR]: 2.91, 95% CI [confidence interval]: 1.03‐8.33, P = .044), baseline ECOG‐PS 2 to 3 (HR: 3.88, 95% CI: 1.77‐8.46, P < .001]), dyspnoea (HR: 3.02, 95% CI: 1.31‐6.96, P = .009), a respiratory rate ≥ 24 (HR: 2.24, 95% CI: 1.02‐4.92, P = .046) and sepsis (HR: 3.97, 95% CI: 1.78‐8.88, P < .001). Of the 76 survivors, 73.6% had a follow‐up visit. Of those, 33.9% had their cancer controlled and 23.2% had progressed. Thirty‐five survivors were receiving anticancer treatment before COVID‐19 diagnosis though 14 had to discontinue the treatment. Eight survivors without previous anticancer therapy started therapy. The median time to start anticancer therapy after COVID‐19 was 45 days (interquartile range: 28‐61). In conclusion, 90‐day mortality in patients with ST and COVID‐19 was 33.9%; current smoker status, poor ECOG‐PS, dyspnoea, respiratory rate ≥24 and sepsis were independent risk factors for mortality; and survivors did not restart their anticancer treatment until 1.5 months after COVID‐19 diagnosis.

9090 Background: We identified factors associated with better OS for previously treated, PD-L1–expressing advanced NSCLC using data from KEYNOTE-010 (NCT01905657; Herbst et al. Lancet. 2016;387:1540-50), in which pembrolizumab had superior OS over docetaxel. Methods: 1033 patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or docetaxel 75 mg/m2 Q3W. Response was assessed per RECIST v1.1 by independent central review. Multivariate analyses were performed using a Cox proportional hazards regression model on OS in the pembrolizumab arms. A set of variable selection methods was applied to 19 baseline demographic and disease characteristics, including smoking status, and identified 7 factors that contributed to OS. Data cut was September 30, 2016. Results: Adjusted hazard ratios (HRs) for the factors in the pembrolizumab arm from the model are shown in the Table. Updated OS with an additional 6 months of follow-up from this data lock for KEYNOTE-010 will be presented. Conclusions: While the overall result of KEYNOTE-010 revealed improved OS with pembrolizumab compared with docetaxel in previously treated patients with PD-L1–positive advanced NSCLC, exploratory, post hoc multivariate analyses showed that some laboratory and tumor characteristics such as nonsquamous histology, normal baseline lactate dehydrogenase (LDH), PD-L1 TPS ≥50%, and wild-type EGFR mutation status were associated with better OS among patients treated with pembrolizumab. Clinical trial information: NCT01905657. [Table: see text]